Sand Fly–Associated Phlebovirus with Evidence of Neutralizing Antibodies in Humans, Kenya
David P. Tchouassi
, Marco Marklewitz, Edith Chepkorir, Florian Zirkel
1, Sheila B. Agha, Caroline C. Tigoi, Edith Koskei, Christian Drosten, Christian Borgemeister, Baldwyn Torto, Sandra Junglen
2 , and Rosemary Sang
2
Author affiliations: International Centre of Insect Physiology and Ecology, Nairobi, Kenya (D.P. Tchouassi, E. Chepkorir, S.B. Agha, C.C. Tigoi, B. Torto, R. Sang); Charité-Universitätsmedizin Berlin, Berlin, Germany (M. Marklewitz, F. Zirkel, C. Drosten, S. Junglen); German Center for Infection Research, Berlin (M. Marklewitz, F. Zirkel, C. Drosten, S. Junglen); Center for Virus Research, Kenya Medical Research Institute, Nairobi (E. Koskei, R. Sang); University of Bonn, Bonn, Germany (C. Borgemeister)
Main Article
Figure 4
Figure 4. Neutralizing activity of novel sand fly–associated phlebovirus Ntepes virus from Kenya in relation to other selected members of the Phlebovirus genus. Anti-GFV and anti-KARV samples were tested along with 26 human serum samples. GFV, Gabek Forest virus; H, human; KARV, Karimabad virus; NPV, Ntepes virus; NT, neutralizing test; RVFV, Rift Valley fever virus.
Main Article
Page created: March 17, 2019
Page updated: March 17, 2019
Page reviewed: March 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.